Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
36.7 HKD | +3.09% | +1.24% | -25.36% |
Apr. 30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
Apr. 29 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.36% | 1.27B | |
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Biosciences Completes Data Unblinding for Phase 3 Study of Eczema Treatment; Shares Rise 8%